<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65383">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01817738</url>
  </required_header>
  <id_info>
    <org_study_id>CV-9104-004</org_study_id>
    <nct_id>NCT01817738</nct_id>
  </id_info>
  <brief_title>Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-Derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients With Metastatic Castrate-refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CureVac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CureVac GmbH</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the new RNActive-derived prostate cancer
      vaccine CV9104 prolongs survival in patients with asymptomatic or minimally symptomatic
      metastatic  prostate cancer that is castrate resistant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is the first clinical study with the new prostate cancer vaccine CV9104. This
      vaccine is composed of 6 RNActive-based compounds, each encoding for an antigen that is
      overexpressed in prostate cancer compared to healthy tissues. RNActive-based vaccines are a
      novel class of vaccines based on messenger RNA.

      The study is a double-blind randomized placebo-controlled phase I/II trial in men with
      asymptomatic- minimally symptomatic metastatic castrate-refractory prostate cancer.

      The phase 1 (safety lead- in) part of the trial has the primary objective to assess the
      safety of CV9104 and to determine the dose for the randomized phase II part.

      The primary objective of the phase II part is to compare overall survival in patients
      treated with CV9104 compared to patients treated with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase I (Safety Lead-In): Occurence of dose-limiting toxicity (DLT) during the first 4 weeks of treatment (after administration of 3 vaccinations and after a 1 week observation period</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety Lead in Portion:
Patients will receive CV9104 at a starting dose of 1920 µg in weeks 1, 2 and 3. Safety lead-in patients will be observed for DLTs until 1 week after Vaccination 3 (week 4). In case no DLTs will be observed vaccinations will continue in weeks 5, 7, 9, 12, 15, 18 and 24, then every 6 weeks for up to 12 months after the first vaccination and then every 3 months thereafter until one of the criteria for study treatment discontinuation is met</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II (Randomised Portion): Overall Survival from time of randomisation- up to 3.5-4 years.</measure>
    <time_frame>Overall survival will be assessed during the lifetime of the study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival from date of randomisation</measure>
    <time_frame>Every 3 months for up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival from start of first subsequent systemic therapy</measure>
    <time_frame>Every 6 months until 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change to maximal and to minimal PSA from baseline and before start of first subsequent systemic cancer therapy</measure>
    <time_frame>Every 3 months up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular and humoral immune response rate against the 6 antigens encoded by CV9104</measure>
    <time_frame>Immune responses will be assessed at baseline ,in week 6 and week 24 after start of vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline FACT P score and subscores</measure>
    <time_frame>Assessments at baseline, weeks 5,9,18,24 and every 3 months for up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline EQ-5D score and pain sub-score</measure>
    <time_frame>Assessments at baseline, weeks 5, 9,18, 24 and thereafter every 3 months for up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>CV9104</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CV9104 intradermal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intradermal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CV9104</intervention_name>
    <description>Intradermal injection of CV9104</description>
    <arm_group_label>CV9104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal injection of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male, age ≥18 years

          2. Histologically confirmed castrate refractory metastatic adenocarcinoma of the
             prostate with progressive disease after surgical castration or during androgen
             suppression therapy including a GNRH agonist or antagonist and after at least 1
             additional anti-hormonal manipulation; and serum testosterone level of &lt; 50 ng/dL or
             &lt; 1.7 nmol/L

             Progression will be confirmed either

               -  radiologically or

               -  by 2 consecutive rises of PSA, measured at least 1 week apart, resulting at
                  least in a 50% increase over the nadir and a PSA &gt; 2 ng/mL.

               -  An antiandrogen withdrawal response must have been excluded after
                  discontinuation of antiandrogen therapy for at least 6 weeks.

          3. Metastatic disease confirmed by imaging

          4. ECOG performance status 0 or 1

        Key Exclusion Criteria:

          1. Previous immunotherapy for PCA (e.g.  sipuleucel-T [Provenge®], experimental cancer
             vaccines or ipilimumab [Yervoy®]).

          2. Treatment with any investigational anticancer agents within 4 weeks prior to first
             dose of study drug

          3. Systemic treatment with immunosuppressive agents

          4. Active skin disease (atopic eczema, psoriasis) in the areas for vaccine injection
             (upper arms or thighs) preventing the administration of i.d. injections into areas of
             healthy skin.

          5. History of or current autoimmune disorders

          6. Primary or secondary immune deficiency.

          7. Seropositive for human immunodeficiency virus, hepatitis B virus (except after
             hepatitis B vaccination) or hepatitis C virus infection.

          8. Symptomatic congestive heart failure (New York Heart Association 3 or 4), unstable
             angina pectoris or myocardial infarction, significant cardiac arrhythmia, history of
             stroke or transient ischemic attack, all within 6 months prior to enrolment or severe
             hypertension according to WHO criteria or uncontrolled hypertension at the time of
             enrolment (systolic blood pressure ≥ 180 mm Hg)´

          9. Previous chemotherapy for metastatic PCA.

         10. Previous anti-hormonal treatment with abiraterone or any other investigational
             anti-hormonal treatment.

         11. Cancer-related pain requiring opioid narcotics within 28 days before enrolment or an
             average pain score of &gt; 3 on a visual analogue scale.

         12. Presence of visceral metastases.

         13. History of other malignancies other than PCA over the last 5 years (except basal cell
             carcinoma of the skin).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnulf Stenzl, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universityhospital of Tübingen; Dept. of Urology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krajská zdravotní, a.s. - Nemocnice Chomutov, o.z.Onkologické oddělení</name>
      <address>
        <city>Chomutov</city>
        <zip>430 12</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Olomouc, Urologická klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiscan, a.s, Oddělení klinické a radiační onkologie</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice, Urologické oddělení</name>
      <address>
        <city>Praha</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajská zdravotní, a.s. - Masarykova nemocnice Ústí nad Labem</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen Klinik für Urologie</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban Klinik für Urologie</name>
      <address>
        <city>Berlin</city>
        <zip>D-10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden Klinik und Poliklinik für Urologie</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgische Universitätsklinik Freiburg Klinik für Urologie</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationales Zentrum für Tumorerkrankungen Medizinische Onkologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie am Nordplatz</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMM Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marklleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Klinik und Poliklinik der Technischen Universität München Klinikum Rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Klinik und Poliklinik für Urologie</name>
      <address>
        <city>Münster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienpraxis für Urologie</name>
      <address>
        <city>Nürtingen</city>
        <zip>D-72622</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum</name>
      <address>
        <city>Offenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Klinik</name>
      <address>
        <city>Planegg</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Urologie</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia Krakow</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Urologiczne Sp. z o.o.</name>
      <address>
        <city>Mysłowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Magodent, Centrum Medyczne Ostrobramska, Oncologii Klinicznej i Chemíoterapii</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA, Klinika Onkologii I Hematologii</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Sw. Elżbiety</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut M. Curie-Skłodowskiej</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki, Katedra i Klinika Urologii i Onkologii Urologicznej</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profesorskie Centrum Medyczne OPTIMUM Wrocław</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Madrid Norte Sanchinarro Centro Integral Oncológico Clara Campal (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Virgen de la Victoria Campus Universitario de Teatinos s/n</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra Departamento de Oncología</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Santiago Departamento de Oncología</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15703</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Sahlgrenska Universitetssjukhuset Urologmottagningen</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus Malmö Urologmottagningen</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna Urologiska kliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset Urologmottagningen</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Örebro Urologmottagningen</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel Medizinische Onkologie</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Chur Department Innere Medizin Hämatologie und Onkologie</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen Department Innere Medizin Hämatologie Medizinische Onkologie</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Borough of Wirral</city>
        <zip>CH64 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital Department of Oncology</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.curevac.de</url>
    <description>Click here for more information about CureVac</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Castrate-refractory</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
